image
Healthcare - Medical - Devices - NASDAQ - US
$ 4.01
2.04 %
$ 23.6 M
Market Cap
-0.8
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one VVOS stock under the worst case scenario is HIDDEN Compared to the current market price of 4.01 USD, Vivos Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one VVOS stock under the base case scenario is HIDDEN Compared to the current market price of 4.01 USD, Vivos Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one VVOS stock under the best case scenario is HIDDEN Compared to the current market price of 4.01 USD, Vivos Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
13.8 M REVENUE
-13.87%
-17.3 M OPERATING INCOME
30.90%
-13.6 M NET INCOME
43.04%
-11.9 M OPERATING CASH FLOW
39.01%
-853 K INVESTING CASH FLOW
7.68%
10.9 M FINANCING CASH FLOW
0.00%
3.86 M REVENUE
-4.79%
-2.5 M OPERATING INCOME
-29.08%
-2.62 M NET INCOME
-35.60%
-4.19 M OPERATING CASH FLOW
-37.37%
-192 K INVESTING CASH FLOW
-220.00%
3.79 M FINANCING CASH FLOW
-48.82%
Balance Sheet Vivos Therapeutics, Inc.
image
Current Assets 2.46 M
Cash & Short-Term Investments 1.64 M
Receivables 202 K
Other Current Assets 616 K
Non-Current Assets 8.27 M
Long-Term Investments 0
PP&E 4.7 M
Other Non-Current Assets 3.57 M
Current Liabilities 7.29 M
Accounts Payable 2.14 M
Short-Term Debt 1.31 M
Other Current Liabilities 3.83 M
Non-Current Liabilities 3.03 M
Long-Term Debt 1.52 M
Other Non-Current Liabilities 1.51 M
EFFICIENCY
Earnings Waterfall Vivos Therapeutics, Inc.
image
Revenue 13.8 M
Cost Of Revenue 5.53 M
Gross Profit 8.27 M
Operating Expenses 25.6 M
Operating Income -17.3 M
Other Expenses -3.71 M
Net Income -13.6 M
RATIOS
59.93% GROSS MARGIN
59.93%
-125.32% OPERATING MARGIN
-125.32%
-98.42% NET MARGIN
-98.42%
-3304.87% ROE
-3304.87%
-126.59% ROA
-126.59%
-364.05% ROIC
-364.05%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vivos Therapeutics, Inc.
image
Net Income -13.6 M
Depreciation & Amortization 621 K
Capital Expenditures -803 K
Stock-Based Compensation 0
Change in Working Capital 2.86 M
Others 27 K
Free Cash Flow -12.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vivos Therapeutics, Inc.
image
VVOS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Vivos Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jun 20, 2023
Bought 7.42 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 14000
0.53 USD
1 year ago
Jun 16, 2023
Bought 2.65 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 5000
0.53 USD
1 year ago
Jun 16, 2023
Bought 5.4 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 10000
0.54 USD
1 year ago
Jun 15, 2023
Bought 10.5 USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 21
0.5 USD
1 year ago
Jun 14, 2023
Bought 4.9 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 10000
0.49 USD
2 years ago
Dec 23, 2022
Bought 10 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 20000
0.5 USD
2 years ago
May 31, 2022
Bought 16.2 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 8000
2.03 USD
3 years ago
Sep 21, 2021
Bought 21.5 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 5000
4.31 USD
3 years ago
Aug 17, 2021
Bought 15 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 5000
3 USD
3 years ago
May 25, 2021
Bought 5.29 K USD
Amman Bradford K.
Chief Financial Officer
+ 1000
5.29 USD
3 years ago
May 25, 2021
Bought 21.5 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 4000
5.38 USD
4 years ago
Dec 24, 2020
Bought 7.38 K USD
Amman Bradford K.
Chief Financial Officer
+ 1000
7.38 USD
4 years ago
Dec 23, 2020
Bought 7.27 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 1000
7.2669 USD
4 years ago
Dec 11, 2020
Bought 4.25 K USD
Huntsman Ronald Kirk
Chief Executive Officer
+ 500
8.5 USD
7. News
Best Momentum Stocks to Buy for January 8th VVOS, DXC and YELP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024. zacks.com - 3 weeks ago
New Strong Buy Stocks for January 8th SONY, VVOS, DXC, LIND and FNCO have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024. zacks.com - 3 weeks ago
Vivos Therapeutics announces funding boost Vivos Therapeutics (NASDAQ:VVOS) has announced definitive agreements for a registered direct offering and concurrent private placement expected to generate up to $6.9 million in gross proceeds The medical device company, which specializes in treatments for sleep-related breathing disorders, said the offering involves the sale of 709,220 shares at $4.935 per share, priced at-the-market under Nasdaq rules, generating gross proceeds of approximately $3.5 million before expenses. Additionally, the company will issue unregistered short-term warrants in a concurrent private placement. proactiveinvestors.com - 1 month ago
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 709,220 shares of its common stock at a purchase price of $4.935 per share in a registered direct offering priced at-the-market under Nasdaq rules. globenewswire.com - 1 month ago
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets. Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 2 months ago
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3 Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses.  Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million in the same period last year. proactiveinvestors.com - 2 months ago
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. globenewswire.com - 2 months ago
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment Vivos Therapeutics (NASDAQ:VVOS) announced that the American Medical Association (AMA) has granted new CPT codes for the company's Vivos CARE oral medical devices. Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos' devices, designed to treat obstructive sleep apnea (OSA) in both adults and children. proactiveinvestors.com - 3 months ago
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children globenewswire.com - 3 months ago
Vivos Therapeutics raises $4.3 from institutional investors Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each. The company said that no stock purchase warrants are being issued in this at-the-market offering. proactiveinvestors.com - 4 months ago
Vivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatment Vivos Therapeutics (NASDAQ:VVOS) announced that it has received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17 using its proprietary oral medical device. This non-invasive, orthodontic-based solution offers an alternative to traditional treatments like adenotonsillectomy, which may not always be effective long-term. proactiveinvestors.com - 4 months ago
8. Profile Summary

Vivos Therapeutics, Inc. VVOS

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 23.6 M
Dividend Yield 0.00%
Description Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Contact 9137 Ridgeline Boulevard, Highlands Ranch, CO, 80129 https://vivos.com
IPO Date Dec. 11, 2020
Employees 114
Officers Ms. Stephanie Huebner Senior Vice President of Dental Service Integration Ms. Susan McCullough Co-Founder & Executive Vice President of Operations Mr. R. Kirk Huntsman Co-Founder, Chairman of the Board & Chief Executive Officer Ms. Ruth Hembree Senior Vice President of Practice Services Mr. Bradford K. Amman Chief Financial Officer, Treasurer & Secretary Mr. John Ballard Senior Vice President of Technology Mr. Nicholas M. DeGennaro Senior Vice President of Medical Integration Division Mr. Todd Huntsman Co-Founder & Senior Vice President of Product and Technology Ms. RaeAnn Byrnes Co-Founder and Senior Vice President of Events & Clinical Advisory Services